CD4 and pancreatic neoplasm: Higher VAS score and decreased CD4+ T cell ratio after HIFU treatment may be potential survival risk factors for patients with unresectable pancreatic cancer, which can be easily obtained in clinical work and help to evaluate patients' feedback on HIFU therapy early.